Original paper
Abstract 9384: Evolocumab, a Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitor, Reduces Doxorubicin, Trastuzumab and Nivolumab Induced Cardiotoxicity Through Mtorc1 and Myd88 Related Pathways
Abstract
Introduction: The PCSK9 inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the FOURIER randomized clinical trial. Recent studies indicates the crucial involvement of PCSK9 in regulation of cardiac cell metabolism and survival. Doxorubicin and trastuzumab-induced cardiotoxicity still remains a clinically relevant problem in cancer patients. Patients treated with nivolumab experienced myocarditis,...
Paper Details
Title
Abstract 9384: Evolocumab, a Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitor, Reduces Doxorubicin, Trastuzumab and Nivolumab Induced Cardiotoxicity Through Mtorc1 and Myd88 Related Pathways
Published Date
Nov 16, 2021
Journal
Volume
144
Issue
Suppl_1